Ardent Health Inc.

Ardent reported second-quarter 2026 revenue of $1.62 billion and adjusted EBITDA of $115 million. Surgeries declined 2.9% year over year and admissions declined 1%; adjusted admissions increased 2.5%, while net patient service revenue per adjusted admission declined 3.9%. SW&B grew 0.7% year over year, contract labor spend fell 42%, and contract labor as a percentage of SW&B improved to 2.2% from 3.8% a year ago. Operating cash flow was $197 million in the quarter versus $117 million a year ago, and first-half operating cash flow was $137 million, up 47% from $93 million in the first half of 2025. For full-year 2026, management maintained revenue guidance of $6.4 billion to $6.7 billion and adjusted EBITDA guidance of $485 million to $535 million. Revenue is expected to skew toward the lower end of the range because of softer volumes, while EBITDA guidance incorporates an approximate $25 million headwind from lower volumes that management expects to offset with $20 million to $30 million from IMPACT savings and payer repricing. Management also reiterated its $35 million exchange headwind assumption for the year and said third-quarter adjusted EBITDA should improve from the $115 million reported in Q2 and approach Q1's $124 million.

Dave Caspers emphasized that Ardent has a strong platform but needs more consistency and operational rigor. He framed IMPACT, Capacity IQ, and service-line rationalization as central to improving margins, standardizing operations, and directing capital toward higher-return opportunities such as cardiology and women's and children's services. His tone was constructive and disciplined, repeatedly stressing faster execution, clearer accountability, and a willingness to act if assets or service lines are not a long-term fit.

Alfred Lumsdaine focused on the quarter's volume softness, saying surgeries were down materially in April and May before recovering in June, and noted that July was still below original expectations but better than April and May. He cited $115 million of Q2 adjusted EBITDA, $197 million of operating cash flow, $724 million of cash, $1.1 billion of debt, $992 million of total available liquidity, and net leverage of 0.8x. He said the company expects $15 million to $20 million of additional savings this year from structural changes plus $5 million to $10 million of higher earnings from one payer renewal, taking IMPACT savings to at least $70 million, and he said the full-year EBITDA outlook remains intact despite a roughly $25 million volume headwind.

Analysts focused on how much of the payer contract opportunity remains, what drove the inpatient surgery weakness, and whether June and July volume improvement was broad-based or temporary. Management said payer pricing opportunities exist across most markets, that the inpatient decline was largely a shift from inpatient to outpatient tied to procedures moving off the inpatient-only list, and that the economics of that shift were modest at about $1 million to $2 million of net impact in the quarter. On volumes, management said the recovery in June and July was broad-based but that they are using Q2 run-rate assumptions for the back half because the environment remains volatile and macro pressures could persist.